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The papanicolaou society of cytopathology (PSC) has developed
a set of guidelines for pancreatobiliary cytology including indica-
tions for endoscopic ultrasound (EUS) guided fine-needle aspira-
tion (FNA) biopsy, techniques of EUS-FNA, terminology and
nomenclature for pancreatobiliary cytology, ancillary testing, and
postprocedure management. All documents are based on the
expertise of the authors, a review of the literature, discussions of
the draft document at several national and international meetings
over an 18 month period and synthesis of online comments of the
draft document on the PSC web site [www.papsociety.org]. This
document selectively presents the results of these discussions and
focuses on the follow-up and treatment options for patients after
procedures performed for obtaining cytology samples for the
evaluation of biliary strictures and solid and cystic masses in the
pancreas. These recommendations follow the six-tiered terminol-
ogy and nomenclature scheme proposed by Committee III. Diagn.
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The successful performance of any medical procedure is
operator dependent. In the case of bile duct brushings and/
or endoscopic ultrasound guided fine-needle aspiration
(EUS-FNA) of pancreatic lesions, a successful outcome
depends on the performance of a dedicated team. The
interventionalist must accurately identify and biopsy the
target tissue as well as obtain sufficient cellular material
for interpretation. The cytologist must make a good qual-
ity, interpretable smear or other satisfactory preparation, be
it a liquid based cytology, cell-block or sample for genetic
analysis. Finally, the cytopathologist who analyzes the
sample must be well-trained and experienced in interpreta-
tion of rapid on site evaluations (ROSE) and final slides,
or at least have adequate training and the backup of senior
more experienced colleagues. Additionally, the diagnosis
of pancreatic lesions is helped by a multidisciplinary
approach involving radiologic and clinical input. This
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multidisciplinary component is often not recognized or
investigated in the various studies published in the litera-
ture regarding the sensitivity, specificity, and predictive
values of pancreatic/biliary duct brushings and EUS-
FNA.1–4
The clinician managing the patient needs to have confi-
dence in the cytologic diagnosis. To this end, the cytopa-
thology team should regularly demonstrate their findings
at multidisciplinary case conferences and, where appropri-
ate, during ROSE. A double-headed microscope can
quickly acquaint the interventionalist with the yield of
their brushings or FNA. The interventionalist can make
this a two-way learning experience by sharing the radio-
graphic images of the pancreatic lesion being biopsied.
Imaging will inevitably give valuable clues to the exis-
tence, diagnosis and extent of the pancreatic lesion. This
information will narrow the diagnostic possibilities and
help optimize the cytologic interpretation. Dual phase,
contrast enhanced spiral computed tomography (CT) can
establish the solid, cystic, confined, or infiltrative nature
of a lesion, as well as provide information about potential
metastatic sites in nearby organs or regional lymph
nodes.5 In cases where actual tissue sampling is neces-
sary, core needle biopsy may need to be performed.
ROSE of a cytologic touch preparation from the core
biopsy may prove to be very valuable. The results can be
communicated directly at the same procedure, just as in
an FNA, ROSE of a touch preparation can confirm
whether the interventionalist has obtained a significant
sample, provide direction to obtain additional material if
the original biopsy was not successful, or if material is
needed for ancillary stains or procedures.
Cytologic sampling can be achieved by endoscopic ret-
rograde duct brushing (DB), percutaneous fine-needle
aspiration (pFNA), or EUS guided FNA (EUS-FNA). For
cystic pancreatic lesions greater than 2 cm, a cytobrush
passed down a 19-gauge needle may be added to routine
FNA. In certain instances, core biopsy to obtain adequate
tissue can be performed with a 22–25 Gauge FNA needle,
although it is more usual to gain core biopsy type sam-
ples with needles 19 gauge and larger.6–9
The purpose of this workgroup effort is to discuss the
options regarding and management of patients following
cytologic diagnoses made by biliary brushing or FNA
cytology, using the terminology developed by the Pancre-
atic/Biliary Guideline Committee III.
Follow-Up in Relation to the Proposed Diagnostic
Terminology
Nondiagnostic
A nondiagnostic cytology sample is defined as a sample
that is inadequate for interpretation due to whatever
cause; there is not enough cytological material to make
any diagnostic comment. For pancreatic lesions, a simple
cell count to determine sample adequacy as is done in
thyroid FNA is not enough. Obtaining pancreatic cytology
samples is much more involved and often has more seri-
ous implications than FNA of superficial sites. The cyto-
logic diagnosis must explain and be consistent with the
clinical and radiologic findings no matter the number of
cells or cellular groups in the cytology sample. It is sug-
gested that only up to 4 passes be attempted, after which
the FNA procedure’s opportunity to obtain diagnostic
material decreases. This has demonstrated in the pancreas
and in other sites.10–13
With an inadequate FNA or brushing, clinical manage-
ment becomes solely dependent on the clinical and imag-
ing findings and is more insecure. If diagnostic
confidence in the imaging and clinical findings are high,
the team may elect to proceed directly to laparotomy to
obtain diagnostic material via tru-cut needle, incisional,
or excisional biopsy.
If the first attempt at cytological diagnosis is by bile
duct brushings, then a second bile brushing attempt or
EUS-FNA of any mass lesion of the distal hepatic, mid/
proximal bile duct, or intrapancreatic common bile duct
should be attempted. If the first attempt was by percuta-
neous FNA then it may be most reasonable to use EUS-
FNA, even if this means moving the patient to an institu-
tion better suited at performing EUS-FNA. If the first
attempt was EUS-FNA, reassessment of the EUS findings
and other imaging should be undertaken, followed by a
review of the FNA line of approach. Although repeat
EUS-FNA is a costly procedure, it is still a less expensive
and less invasive option than biopsy via laparoscopy or
laparotomy.10,14
Repeat EUS-FNA of cystic lesions of the pancreas
should be considered carefully as it has been recom-
mended that only one draining pass be made because of
risks as high as 14% of infection even if there is no cellu-
lar cytological material. Correlation with imaging is man-
datory.15 This infection risk can be reduced to under 3%
by using intraprocedural intravenous antibiotics, such
as fluoroquinolone and then oral antibiotics for 3–5
days.16–19
Negative
A negative cytology sample is defined as a cytological
interpretation that is negative for malignancy and any cel-
lular atypia; preferably a diagnosis is made that is specific
for a benign non-neoplastic condition. A descriptive nega-
tive interpretation implies that the sample is adequately
cellular and that no cytological atypia is identified in the
evaluated cytology sample. This includes the presence of
normal pancreatic tissue in the appropriate clinical setting
such a vague fullness on imaging and no distinct mass
lesion. A negative cytology interpretation that is
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descriptive without a diagnosis of a specific condition
such as chronic pancreatitis or pseudocyst is not synony-
mous with a benign lesion.
Entities that fall under this category include acute,
chronic, and autoimmune pancreatitis, pseudocyst, ectopic,
or intrapancreatic splenule and lymphoepithelial cyst.
The multidisciplinary team or individual in charge of
the patient’s care must perform the “triple test,” i.e., an
assessment that includes the clinical presentation, radio-
logic findings, and cytopathology. If any one of the ele-
ments of the “triple test” are discrepant it is mandatory to
reassess that component, and if found on review to be
sound, then the overall diagnosis and other elements have
to be reassessed.6,8,9,13,15 For example, if EUS demon-
strates biliary or pancreatic duct dilation, or radiology
finds regional lymphadenopathy, it is more likely that
there is a malignancy despite a non-diagnostic or negative
cytology report. In such cases the interventionalist might
be more aggressive in their attempts at obtaining material
via FNA or proceed to laparoscopy or laparotomy.6,15,20–
23 Pancreatic EUS-FNA has a very high specificity with
very few false positive interpretations; however, false
negative interpretations are not uncommon due to sam-
pling and interpretive errors, which impact the sensitivity
of the test.
Postprocedural management of specific benign diagno-
ses include the following:
Acute Pancreatitis is usually managed by an institu-
tional specific protocol, which commonly consists of ces-
sation of oral intake, intravenous fluid hydration, and
narcotic analgesia. Patient recovery is largely monitored
by the patient’s symptoms and the physican’s examina-
tion. The etiology of the pancreatitis is sought to prevent
future episodes. Significant complications of pancreatitis
including pseudocyst, hemorrhage, obstruction, and pan-
creatic necrosis may occur. Pseudocysts commonly occur
in a background of pancreatitis and EUS-FNA may have
a significant risk of post procedure infection. Life support
may be necessary in severe cases of acute pancreatitis,
and surgical intervention with resection and debridement
is reserved for cases where medical management fails.
Post-ERCP pancreatitis may complicate up to 5% of
ERCP procedures. Most cases are mild but rare fatalities
are reported.24 Bile duct brushings have been associated
with potential exacerbation of acute pancreatitis. EUS-
FNA is an excellent alternative to ERCP/brushings for
evaluation of extra-hepatic bile duct and periductal
lesions that appear to arise in the intrapancreatic ducts
and gallbladder.12,16,25,26
Chronic pancreatitis is characterized by chronic
abdominal pain due to progressive inflammation, destruc-
tion of pancreatic tissue, parenchymal replacement by
fibrous tissue, and resultant impairment of pancreatic exo-
crine and endocrine function. Therapy is aimed at identifi-
cation and removal of the cause of the pancreatitis,
treating the patient’s pain, and managing pancreatic fail-
ure (e.g., enzyme digestive replacement for exocrine fail-
ure and oral hypoglycemic or exogenous insulin for
endocrine failure).25
Autoimmune pancreatitis (AIP) is a rare disease. The
radiologic pattern of AIP can be distinctive with a dif-
fusely enlarged pancreas, but may also mimic pancreatic
cancer. Elevated serum IgG4, the clinical context and
response to steroids may help confirm the diagnosis. Ste-
roids are the main treatment.16,27,28 There are no known
specific complications of EUS-FNA of autoimmune
pancreatitis.29
Pseudocysts usually occur in a background of chronic
pancreatitis or a history of acute pancreatitis related to
trauma. Once diagnosed their management is dependent on
their size and symptomatology and presence/absence of
ductal communication. Treatment may involve endoscopic
stenting, internal drainage (endoscopic or operative), or
external drainage (percutaneous).30,31 EUS-FNA may have
a significant risk of postprocedural infection.16,18,24
Lymphoepithelial cysts are relatively rare lesions that
can be managed conservatively if the patient is asymp-
tomatic and the diagnosis can be securely established by
imaging and EUS-FNA. They need to be distinguished
from mucinous cystic lesions of the pancreas. EUS-FNA
can establish the diagnosis based on the presence of
benign squamous cells, keratotic debris, and the lack of
mucin. There are no specific complications of FNA of
lymphoepithelial cysts.13,32
Accessory spleen or splenules (splenucules) can occur
in the pancreas or in the splenic hilum adjacent to the
pancreas. They are commonly found incidentally on CT
radiologic examination and even with EUS may raise a
differential diagnosis that includes neoplasms. FNA can
be diagnostic. No complications (hemorrhage) have been
reported with FNA. If a clinical question remains after
identification or the diagnosis is uncertain, resection is
curative.
Hydatid cysts have been reported in the pancreas or
impinging on the pancreas. FNA poses a potential risk of
an anaphylactic reaction following leakage of cyst con-
tents and activation of Type 1 hypersensitivity. FNA
where the diagnosis was suspected prior to the procedure
based on imaging findings has not been reported, and the
actual risk with FNA is not known. Therapy is careful
surgical resection.18
Atypical
An atypical interpretation is defined as cytoplasmic,
nuclear, or architectural features that are not consistent
with normal or reactive cellular components of the pan-
creas or bile ducts, but features are not sufficient to
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indicate a neoplasm or overt malignancy. This interpreta-
tion calls for additional diagnostic testing.
In other organ systems the usual response to an atypi-
cal cytologic interpretation is a repeat procedure. For
uterine cervical cytology or thyroid FNA the performance
of a repeat procedure is relatively easy with the major
problem being rescheduling of the patient back into the
clinic. The logistics of repeat EUS, ERCP, or percutane-
ous FNA are much more involved and require the serv-
ices of a number of individuals and utilization of
expensive equipment. The resource utilization and costs
of operative biopsy are even greater. The resource prob-
lem causes immediate repeat diagnostic procedure to be a
nontrivial issue. The appropriate course of action is
dependent on a multidisciplinary review, the functional
status of the patient and the wishes of the patient after
clinical consultation.
Ancillary testing in some cases may assist determina-
tion of the management of the patient after an atypical
cytological diagnosis. Just as positivity for high-risk
human papilloma virus increases the likelihood of disease
in an indeterminate “atypical” cervical smear, atypical
pancreatic cytology in combination with a number of bio-
chemical tests may be helpful in clinical management and
follow-up. Although not routinely performed, Dpc4/
SMAD4 suppressor gene is lost in 55% of pancreatic duc-
tal adenocarcinomas (PDAC), and this finding may add
support to the indeterminate “atypical” interpretation
when imaging is suspicious for adenocarcinoma.
Although not specific for malignancy, detection of mutant
KRAS, which is seen in over 90% of malignancies may
contribution to management decisions in the appropriate
clinical setting.33–35
Neoplastic
Neoplastic: Benign. The major entity in this category,
serous cystic neoplasm (SCN), can be observed or treated
by resection. SCN may or may not have a diagnostic
imaging presentation. When it does, FNA is not per-
formed. When there is uncertainty about the diagnosis,
FNA is performed in an attempt to make a specific diagno-
sis on the one hand, but to at least make a diagnosis of a
nonmucinous cyst. If imaging, cytology, and cyst fluid bio-
chemistry (CEA and amylase) support an interpretation of
a SCN, the patient can be conservatively managed with
observation, with the proviso that the patient is asymptom-
atic and that there is no evidence of significant growth,
which raises the risk of hemorrhage and rupture.17,18,36,37
Neoplastic: Other. Pancreatic neuroendocrine tumor
(PanNET). PanNET present two problems: tumor
growth and spread and hormonal activity. Whether to per-
form surgery and the type of surgery is dependent on
patient age, fitness, and symptoms as well as lesion loca-
tion, size, grade, and stage. With the increasing use of
cross-sectional imaging, very small (1 cm) tumors are
being discovered incidentally in a large number of
patients, many of whom are elderly and with comorbid
conditions increasing surgical risk. PanNETs may grow
very slowly for prolonged periods, and although the
majority (50–60%) eventually exhibits malignant behav-
ior, surgical intervention may not be the best option for
all patients. As such, placing PanNETs in this more
generic category of Neoplastic: Other rather than in the
positive or malignant category increases management
options significantly. Convincing a patient that conserva-
tive management of their incidental 1 cm PanNET is the
best option for them is virtually impossible when diag-
nosed by cytology as malignant.
Genetic testing for germline mutations should be per-
formed if the family or personal history is suggestive of
Multiple Endocrine Neoplasia (MEN 1) or Von Hippel
Lindau Disease. Symptoms usually cause functioning
PanNETs to be discovered at a smaller size than with
nonfunctioning PanNETs. Controlling the symptoms ini-
tially treats symptomatic, functioning PanNET’s. For
example, proton pump inhibitors or high dose histamine
H2-receptor antagonists can oppose hypersecretion of gas-
trin in Zollinger-Ellison syndrome. Secretion of other hor-
mones may be controlled with somatostatin analogs
(Octreotide). Where resection has failed or is impossible,
a number of molecularly based modern treatments are
available including sunitinib (tyrosine kinase inhibitor),
rapmycyin (mTOR inhibitor), and PRRt (peptide receptor
radionuclide therapy).6,38 Functioning PanNET may have
elevated serum pancreatic polypeptide (PP), insulin, C-
peptide, proinsulin, gastrin, vasoactive intestinal peptide
(VIP), glucagon, calcitonin, or somatostatin. Levels for
these hormones should be drawn and monitored during
the therapeutic process. For patients with nonfunctioning
PanNET, serum chromogranin A, is useful for following
treatment response. Pancreatic polypeptide may also be
elevated in apparently nonfunctional PanNET and can
serve as a useful post-treatment marker.39 Local and or
hepatic resection is done for functioning and nonfunction-
ing tumors with the aim of curative resection or debulk-
ing/palliation dependent upon size and location. The





vides guidelines and algorithms for management of func-
tioning and nonfunctioning PanNETs that are available
online.*40–44
*http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#neuroendo-
crine. All rights reserved. To view the most recent and complete
version of the guidelines, go online to www.nccn.org. NATIONAL
COMPREHENSIVE CANCER NETWORKVR , NCCNVR , NCCN
GUIDELINESVR , and all other NCCN Content are trademarks owned
by the National Comprehensive Cancer Network
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For patients with metastatic disease, if the metastatic
disease is restricted to the liver, resection (including the
possibility of hepatectomy and transplantation) is war-
ranted for both functioning and nonfunctioning tumors
with the aim of curative resection or debulking/palliation
dependent on the size and location of the tumor. Emboliza-
tion or radiofrequency ablation may be considered with or
without chemotherapy for liver metastases to decrease
symptoms from hormonally active tumors. Hepatic trans-
plantation may be considered in select cases. Somatostatin
analogs infusion may be indicated in resection of primary
tumors, metastatic lesions, anesthetic procedures, or embo-
lization to avoid hormonal crises. The NCCN
VR
manage-
ment algorithm for metastatic disease that provides detail
is also accessible via the weblink provided below.†44,45
Solid-pseudopapillary neoplasm (SPN). Surgical
resection is the treatment for solid-pseudopapillary neo-
plasm. Approximately 15–20% are malignant with local
recurrence and distant spread most commonly to the liver.
Most patients are cured by resection with 95% or better
survival at five years. Even with hepatic and lymph node
metastases, the tumor shows low aggressiveness.18,46,47
Mucinous cystic neoplasm. Surgical resection is the
treatment of choice for all MCN regardless of grade due to
the expense and anxiety associated with lifelong surveil-
lance of the usual middle-aged female affected by this
neoplasm. Although most are benign, nearly 18% will
undergo malignant transformation. Mural nodularity and
cyst diameter greater than 4 cm are imaging features asso-
ciated with malignant risk. Patients considered surgical
risks with small cysts without high-risk imaging features
may be managed with observation, but must be subjected
to lifelong clinical and radiologic scrutiny to evaluate for
features suggestive of malignant transformation.46,48,49
Intraductal papillary mucinous neoplasms (IPMN). Sur-
gical intervention versus observation depends on the type
of IPMN: IPMN that involve the main duct alone or in
combination with branch-duct cysts (M-IPMN) or branch
duct (BD-IPMN) only cysts.49–51
M-IPMNs are treated by resection. Observation of
mucous extruding from a patulous (“fish-mouth”)
Ampulla of Vater is diagnostic of M-IPMN. Main-duct
dilatation >10 mm is considered a high-risk imaging fea-
ture and surgery is typically performed without preopera-
tive tissue diagnosis. M-IPMN’s are most commonly
lined by intestinal-type epithelial cells and invasive carci-
noma is found in 40–45% with high-grade dysplasia iden-
tified in another 20%52 M-IPMN’s usually occur in the
pancreatic head requiring a pancreatoduodenectomy.
Management options for patients with BD-IPMN are
more controversial. BD-IPMNs are most often benign and
asymptomatic. Increased use of cross-sectional imaging
has greatly increased the detection of these incidentalo-
mas identified in nearly 8% of elderly patients. Since, the
time to malignant transformation is estimated to be about
10 years, many patients, especially those with comorbid
conditions, benefit more by conservative observation than
surgery. The decision to operate is determined by the risk
of malignancy, which in many centers is solely based on
imaging features such as the presence of an enhancing
mural nodule. Worrisome imaging features such as large
cyst size (>3cm) or nonenhancing mural nodule warrant
evaluation with FNA.49 The cytological evaluation of the
cyst contents for high-grade epithelial atypia (e.g., high-
grade dysplasia or invasive carcinoma) is a high-risk fea-
ture as well warranting surgical resection.53 Although the
typical BD-IPMN is lined by low-grade dysplastic gastric
type epithelium, when invasive carcinoma occurs, it is of
the tubular type with the same dismal prognosis as con-
ventional ductal adenocarcinoma.54 As such, the patient
has the best prognosis when premalignant (e.g., preinva-
sive) carcinoma is identified, preferably at the level of
high-grade dysplasia. Demographics (age/gender), family
history of pancreatic cancer, social history of tobacco
usage, obesity, and serum tumor markers (CA19-9, Ha1c)
may also influence the patient’s risk of pancreatic cancer
and, thus, the decision to operate.
A flowchart illustrating the Fukuoka revised guidelines
for management of mucinous cystic neoplasms and intra-
ductal papillary mucinous neoplasms is shown with per-
mission in Figure 1.49
Gastrointestinal stromal tumor (GIST). For localized
GIST, surgical resection with an aim of achieving nega-
tive margins is indicated. For advanced or metastatic c-
Kit1 GIST, the c-Kit tyrosine kinase inhibitor (TKI),
Imatinib, has shown improved clinical response over what
was previously a dismal outlook. Unfortunately, TKI ther-
apy is not a cure and resistance tends to develop. Thus
few patients with advanced disease are cured by chemo-
therapy and remission or stabilization is the current
expectation until new generations of therapeutic agents
are created and tested.
Suspicious
These lesions show severe cellular atypia, suspicious for
invasive ductal carcinoma or other high-grade malignant
neoplasm, for example, an aspirate with a solid-cellular
smear pattern without diagnostic cytological features or
tissue available for confirmatory molecular or immunohis-
tochemical findings supportive of a specific neoplasm
such as PanNET or SPN, which would then allow for the
classification as “Neoplastic: Other.”
As with the benign and atypical interpretations, when
there are discrepant imaging findings suggesting malig-
nancy, and an atypical interpretation, management of the
patient with a “suspicious” cytological interpretation
requires a stringent multidisciplinary review of the clini-
cal and imaging findings. Biochemical and molecular
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analytical markers may increase the sensitivity and speci-
ficity of the interpretation.
If the cytological findings are unexpected and do not
correlate with imaging predictions of a benign lesion,
then repeat brushings or EUS-FNA should be considered,
with the goal of obtaining sufficient tissue for cellblock
preparation and ancillary testing.
If the cytological findings of suspicious for malignancy
do correlate with the imaging findings suggestive of
malignancy, then the patient can be worked up and
staged. This could include laparoscopy with biopsy, fur-
ther EUS-FNA of lymph nodes, PET, and CT scans to
exclude distant metastases. The exact workup is depend-
ent on the availability of these modalities, personnel, and
local established protocols.
Positive/Malignant
The malignant category is definitive for a high-grade
malignancy and should always be accompanied by a spe-
cific diagnosis whenever possible.55
Management relates to the specific type of malignancy
present. Since, conventional ductal adenocarcinoma
(PDAC) or a variant represents 9 of 10 pancreatic malig-
nancies, this interpretation category, more likely than not,
represents PDAC. In some cases, it may not be possible
to define the particular malignancy on cytology alone. In
these cases ancillary tests on cell block or other fluid
based preparations should be done, when available. For
example, it is important to distinguish acinar cell carci-
noma, a high-grade aggressive malignancy, from mimick-
ers such as PanNET. Metastatic malignancy to the
pancreas should always be considered especially when
the imaging or EUS findings are not typical of a pancre-
atic primary or the cytological findings are not
characteristic.
Adenocarcinoma of the Pancreatobiliary Ducts, and
Variants
The current NCCN Clinical Practice Guidelines In Oncol-
ogy (NCCN Guidelines
VR
) for the management of patients
with PDAC are outlined in Tempero et al.56 Currently,
15% of patients are candidates for surgical resection
based upon preoperative staging. Using all available diag-
nostic modalities including high resolution, dual phase
Fig. 1. The Fukuoka revised guidelines for management of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms.49
Diagnostic Cytopathology DOI 10.1002/dc
KURTYCZ ET AL.
368 Diagnostic Cytopathology, Vol. 42, No 4
CT scanning, and EUS, the accuracy of determining
resectability is 85%, but this still leaves one in five lap-
arotomies that will find a nonresectable tumor. Initial lap-
aroscopy may be of further help for detection of occult
metastases reducing the number of unnecessary laparoto-
mies to 10% for body/tail lesions, which tend to be more
advanced at presentation than head/uncinate lesions.
Prior to attempted resection, liver “function tests”
including coagulation tests are necessary to determine the
patient’s functional liver reserve. If liver function tests
fail to return to normal following endoscopic stenting in
patients with biliary obstruction, this may indicate liver
failure from prolonged biliary obstruction or unsuspected
pre-existing liver disease.
Tumors in the head or uncinate process of the pancreas
are treated with pylorus preserving pancreaticoduodenec-
tomy (Whipple’s procedure). Tumors of the body/tail are
treated with distal pancreatectomy and splenectomy. With
surgical resection and adjuvant chemotherapy patients
have a median survival of 18–24 months and a 15–20%
chance of 5-year survival in this limited form of disease.
Serum CA19-9 is elevated in 70–80% of cases of pan-
creatic ductal adenocarcinoma. While not an optimal
screening tool, it is useful to monitor for recurrence and
disease progression in patients demonstrating preoperative
elevated serum CA19-9.
In cases of nonresectable disease, common complications
include pain, jaundice, pancreatic exocrine insufficiency,
and gastric outlet obstruction. Oral narcotic analgesics and
celiac nerve blocks may address the pain when it is due to
invasion of the pancreatic nerves and celiac plexus.
Endoscopic stents are optimal palliation for biliary
obstruction. Stents obstructed by tumor ingrowth can be
restented. Operative biliary bypass may be considered in
cases where patients are explored for cure and found to
be locally unresectable.
Pancreatic exocrine insufficiency may be managed with
exogenous pancreatic enzyme supplementation. Gastric
outlet obstruction is optimally managed with newer gen-
eration endoscopic duodenal stents. If not amenable to
endoscopic stenting, operative gastrojejunal bypass may
be considered in fit patients and a gastrostomy tube may
be placed for palliation in unfit patients.
Less than 10% of tumors resected are Stage I or II.
Overall 5 year survival for all patients with pancreatic
adenocarcinoma is 5% (SEER data 1996–2003).49 Che-
motherapeutic agents gemcitabine, 5-flourouracil, and
paclitaxel have each been shown to improve survival
alone or in combination. Adjuvant gemcitabine on aver-
age increases patient survival 4–6 weeks. Gemcitabine
treatment for unresectable disease also improves survival
several weeks. A recent study indicates this effect may be
enhanced by combination treatment with paclitaxel. Neo-
adjuvant trials have shown slight benefit.57
Approximately 10% of patients who develop pancreatic
cancer have a hereditary component. Another 10% of
patients who develop pancreatic cancer may be predis-
posed by a precancerous (mucinous) pancreatic cystic
lesion. Patients with mucinous pancreatic cysts or a fami-
lial predisposition to pancreatic cancer, may benefit from
screening. Early detection may prevent pancreatic cancer
or detect its presence early enough to optimize the chance
of curative treatment. At present, prevention in these
select groups is the most promising treatment.
Acinar Cell Carcinoma
These tumors are managed surgically and medically in a
similar fashion to pancreatic ductal adenocarcinoma.
High-Grade Neuroendocrine Carcinoma (Small and
Large Cell Type)
These tumors are associated with a rapid clinical course
with the majority of patients having liver metastases at
the time of diagnosis. Treatment is with chemotherapy
regimens similar to small cell lung carcinoma
guidelines.58,59
Pancreatoblastoma
The optimum management of this malignant tumor of
childhood is complete surgical resection. Approximately
half do well with surgical resection. In cases of resectable
disease, adjuvant chemotherapy is recommended with reg-
imens including cisplatin and doxorubicin. Even follow-
ing what appears to be curative resection, there is a
recurrence rate and patients must be followed closely. In
cases of unresectable tumor at initial diagnosis, neoadju-
vant chemotherapy may downstage the tumor enough to
reconsider surgery.60
Lymphoma
Lymphomas are included in this category although not all
lymphomas are “high-grade” per se. Specific treatment
will be subject to medical management directed by the
hematologic workup including histologyic morphology,
flow cytometry, and cytogenetic analysis.
Metastases
The presence of metastatic disease usually indicates wide-
spread dissemination of the primary malignancy and the
management will be dependent on the specific primary
tumor and its histologic grade.
Summary
These guidelines provide a brief overview for patient
treatment and management following the cytological
interpretation of diseases as categorized by the six-tiered
terminology and nomenclature classification system pro-
posed by Committee III (refer to document from
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committee III in this issue). More detailed treatment strat-
egies are provided by surgical and gastrointestinal spe-
cialty organizations [British society of Gastroenterology,
Pancreatic Society of Great Britain, Royal College of
Pathology, Japan Pancreas Society, International Associa-
tion of Pancreatology]60,61 as well as NCCN.
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